ALVO stock forecast, quote, news & analysis
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally... Show more
Why Alvotech (ALVO) Stock Is Down -21% in the Last 30 Days
Key Takeaways
- Alvotech (ALVO) shares declined roughly 21% over the trailing 30 days, retreating from about $5.81 to $4.58 as a strong September rally unwound.
- The pullback comes after a powerful run-up: the stock is still up approximately 50% over the trailing quarter after rebounding from near $3.06 in late July.
- Near-term weakness reflects profit-taking, a Zacks downgrade to "Strong Sell," and lingering concerns over first-half 2026 revenue that fell 31% year over year amid a manufacturing slowdown.
- Fourth-quarter FDA decisions on three biosimilar applications — for Simponi, Eylea, and Prolia/Xgeva — remain the central catalyst, with management reaffirming full-year 2026 guidance.
- Despite the retreat, recent analyst price targets cluster in the $7–$8 range, suggesting the broader investment thesis remains intact.
- For additional detail on valuation and expectations, explore Alvotech's Price Targets, Earnings, and Forecast pages.
- To see how AI-driven trading strategies are positioning across the market, visit Tickeron's Trending AI Robots.
Alvotech (ALVO) Company Overview and Market Position
Alvotech is a global biotechnology company focused exclusively on the development and manufacture of biosimilar medicines — lower-cost, near-identical versions of biologic drugs. Founded by Róbert Wessman in 2013 and headquartered in Luxembourg, the company operates a large-scale manufacturing facility in Reykjavik, Iceland, and is listed on Nasdaq under the ticker ALVO, with additional listings in Iceland and Stockholm.
The company has five biosimilars contributing to product revenue, spanning treatments for autoimmune and inflammatory diseases, eye disorders, and bone conditions — including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab). Its disclosed pipeline includes more than 30 internally developed candidates across autoimmune disorders, eye disorders, and oncology. Alvotech commercializes through a network of strategic partners to reach the United States, Europe, Japan, China, and other global markets. Investors follow the stock for its exposure to the expanding biosimilar market and its steady cadence of regulatory and commercial milestones.
Alvotech (ALVO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ALVO fell approximately 21%, declining from a closing price of $5.81 to $4.58. The move was not a straight line: shares climbed to an intraday peak near $6.15 in late September before fading steadily through October, including a multi-session decline that pushed the stock below its 50-day moving average.
The short-term retreat contrasts sharply with the broader quarterly trend. Over the trailing three months, the stock is still up roughly 50%, having recovered from around $3.06 in late July. In other words, the recent selloff represents a partial retracement of a substantial summer-to-early-autumn rally rather than a reversal of the multi-month uptrend.
What Drove ALVO Stock Price in the Last 30 Days
The 30-day decline was driven primarily by an unwinding of the September rally rather than a single negative event. After Barclays upgraded the stock to Overweight and raised its target to $8 in mid-September, and UBS set a matching $8 target, ALVO surged before momentum faded into month-end. Traders then locked in gains as the stock consolidated well above its 52-week low.
Sentiment was further pressured in late October when Zacks Research downgraded the shares to "Strong Sell" from "Hold," citing an earnings shortfall. The move refocused attention on mixed second-quarter results reported in August, when Alvotech posted an adjusted loss of $0.11 per share versus the $0.05 loss analysts expected, even as revenue of $106 million slightly exceeded the $103 million consensus. First-half revenue declined 31% year over year to about $212 million, reflecting a temporary manufacturing slowdown tied to facility and quality-system upgrades at the Reykjavik site.
Offsetting these headwinds, the FDA approved a higher-yield manufacturing process for SIMLANDI, the company's Humira biosimilar, that more than doubles drug-substance output per batch, and Bank of America reiterated a Buy rating with a $7.00 target in mid-October. However, investors have remained cautious ahead of year-end regulatory decisions.
What Drove ALVO Stock Performance Over the Last Quarter
The roughly 50% quarterly gain was built on steady regulatory and operational progress. In June, Alvotech resubmitted U.S. Biologics License Applications for AVT05 (Simponi), AVT06 (Eylea), and, through its partner, AVT03 (Prolia/Xgeva), addressing the FDA's earlier action letters. The FDA subsequently closed its routine manufacturing inspection of the Reykjavik facility with a Voluntary Action Indicated classification, and the agency accepted the AVT16 application for a proposed interchangeable Entyvio biosimilar.
The company also strengthened its balance sheet during the period, completing an equity offering that raised roughly $165 million in gross proceeds and securing a $75 million term loan, providing about $240 million of new capital. Manufacturing returned to planned operating levels by the end of the second quarter, and management reaffirmed full-year guidance of $650–$700 million in revenue and $180–$220 million in adjusted EBITDA. These developments underpinned the multi-month rally that preceded October's pullback.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots from a much larger universe. While Tickeron offers hundreds of bots that trade thousands of tickers across various strategies, timeframes, and performance metrics, only the top-performing and most relevant strategies are highlighted in this section. Each bot follows a distinct approach — some focus on momentum, others on mean reversion or pattern recognition — giving traders a way to monitor systematic strategies at a glance. For investors tracking names like Alvotech alongside the broader market, this resource offers a complementary, data-driven perspective on where automated strategies are currently finding opportunity.
ALVO Stock Forecast Drivers: What Investors Should Watch Next
The clearest near-term catalyst is the FDA's decision on the resubmitted applications for AVT05, AVT06, and AVT03, anticipated in the fourth quarter with review goal dates around early December. A decision in the ongoing Simponi-related patent litigation is also expected during the quarter. Third-quarter results, scheduled for release on November 11, 2026, will provide visibility on whether the manufacturing recovery is translating into renewed revenue momentum ahead of what management expects to be a strong fourth quarter.
Beyond these milestones, investors should monitor biosimilar pricing dynamics and competition in the U.S. and Europe, the pace of supply rebuilding and product shipments, and the company's elevated debt load and interest costs, which management has flagged as a focus for "healthy de-leveraging" in 2027. Progress on the Entyvio (AVT16) program and the AVT29 high-dose Eylea candidate also represents a longer-horizon growth driver. As with any biopharmaceutical company dependent on regulatory outcomes, the timing and result of FDA actions remain the dominant swing factors for the stock.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALVO in downward trend: price dove below 50-day moving average on October 16, 2026
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 72 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 35 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALVO's RSI Oscillator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 64 cases where ALVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +6.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 116 of 166 cases where ALVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.665) is normal, around the industry mean (8.329). P/E Ratio (-7.500) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric